Tevogen Bio Announces 2025 Annual Meeting
Tevogen Bio Holdings (Nasdaq: TVGN) has announced its 2025 Annual Meeting, scheduled for June 23, 2025, at 11 a.m. Eastern Time via live webcast. Stockholders of record as of April 30, 2025, will vote on two key matters: the re-election of two incumbent director nominees and the ratification of the company's independent registered public accounting firm.
The company will distribute proxy materials to stockholders, including voting instructions. Shareholders must provide their 16-digit control number found on their Notice of Internet Availability, proxy card, or voting instruction form to participate in voting. Meeting results will be disclosed via Form 8-K following the event.
Tevogen Bio Holdings (Nasdaq: TVGN) ha annunciato la sua Assemblea Annuale del 2025, prevista per il 23 giugno 2025 alle ore 11:00 Eastern Time, trasmessa in diretta via webcast. Gli azionisti registrati al 30 aprile 2025 voteranno su due questioni principali: la rielezione di due direttori uscenti e la ratifica della società di revisione contabile indipendente registrata.
L'azienda distribuirà ai soci il materiale per la delega, incluse le istruzioni per il voto. Gli azionisti devono fornire il loro numero di controllo a 16 cifre, che si trova nell'Avviso di Disponibilità su Internet, sulla scheda di delega o sul modulo di istruzioni di voto, per poter partecipare alla votazione. I risultati dell'assemblea saranno comunicati tramite il modulo 8-K dopo l'evento.
Tevogen Bio Holdings (Nasdaq: TVGN) ha anunciado su Junta Anual de 2025, programada para el 23 de junio de 2025 a las 11 a.m. hora del Este, a través de una transmisión en vivo por internet. Los accionistas registrados al 30 de abril de 2025 votarán sobre dos asuntos clave: la reelección de dos directores actuales y la ratificación de la firma independiente de contabilidad pública registrada de la compañía.
La empresa distribuirá materiales de poder a los accionistas, incluyendo instrucciones para votar. Los accionistas deben proporcionar su número de control de 16 dígitos que aparece en su Aviso de Disponibilidad en Internet, tarjeta de poder o formulario de instrucciones de voto para participar en la votación. Los resultados de la reunión se divulgarán mediante el Formulario 8-K después del evento.
Tevogen Bio Holdings (나스닥: TVGN)은 2025년 연례 주주총회를 2025년 6월 23일 오전 11시(동부 시간)에 라이브 웹캐스트로 개최할 예정이라고 발표했습니다. 2025년 4월 30일 기준 주주명부에 등재된 주주들은 두 가지 주요 안건에 대해 투표합니다: 재임 중인 이사 두 명의 재선임과 회사의 독립 공인회계법인 승인 건입니다.
회사는 주주들에게 투표 지침을 포함한 위임장 자료를 배포할 예정입니다. 주주들은 인터넷 이용 가능 통지서, 위임장 또는 투표 지침서에 기재된 16자리 제어 번호를 제공해야 투표에 참여할 수 있습니다. 회의 결과는 행사 후 Form 8-K를 통해 공개됩니다.
Tevogen Bio Holdings (Nasdaq : TVGN) a annoncé sa réunion annuelle 2025, prévue le 23 juin 2025 à 11h00, heure de l'Est, via une diffusion en direct sur le web. Les actionnaires inscrits au 30 avril 2025 voteront sur deux points clés : la réélection de deux administrateurs en fonction et la ratification du cabinet d'audit indépendant enregistré de la société.
La société distribuera aux actionnaires les documents de procuration, incluant les instructions de vote. Les actionnaires doivent fournir leur numéro de contrôle à 16 chiffres, indiqué sur leur Avis de Disponibilité Internet, leur carte de procuration ou leur formulaire d'instructions de vote, pour pouvoir participer au vote. Les résultats de la réunion seront publiés via le formulaire 8-K après l'événement.
Tevogen Bio Holdings (Nasdaq: TVGN) hat seine Hauptversammlung 2025 angekündigt, die am 23. Juni 2025 um 11 Uhr Eastern Time per Live-Webcast stattfinden wird. Aktionäre, die am 30. April 2025 im Aktienregister eingetragen sind, werden über zwei wichtige Punkte abstimmen: die Wiederwahl von zwei amtierenden Direktoren und die Bestätigung der unabhängigen registrierten Wirtschaftsprüfungsgesellschaft des Unternehmens.
Das Unternehmen wird den Aktionären Unterlagen zur Stimmrechtsvertretung zusenden, einschließlich Abstimmungsanweisungen. Aktionäre müssen ihre 16-stellige Kontrollnummer angeben, die sie auf ihrer Benachrichtigung über die Internetverfügbarkeit, der Vollmacht oder dem Stimmrechtsformular finden, um an der Abstimmung teilzunehmen. Die Ergebnisse der Versammlung werden nach der Veranstaltung über das Formular 8-K bekanntgegeben.
- None.
- None.
WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. Eastern Time on June 23, 2025. Stockholders of record as of April 30, 2025, will be asked to vote on the re-election of two incumbent director nominees, and the ratification of the Company’s independent registered public accounting firm.
Tevogen Bio encourages all stockholders of record as of April 30, 2025, to participate in this year’s vote. Proxy materials, including detailed instructions for voting, will be distributed or made available in accordance with Securities and Exchange Commission (“SEC”) regulations to stockholders of record as of April 30, 2025. If you are a stockholder and provide your 16-digit control number, which can be found on your Notice of Internet Availability, proxy card, or voting instruction form, you will be able to vote your shares at the Annual Meeting.
The Company intends to disclose the Annual Meeting voting results on a Form 8-K following the Annual Meeting.
Additional Information and Where to Find It
The Company will file with the SEC a proxy statement on Schedule 14A relating to the Annual Meeting, which will be mailed to the Company’s stockholders of record as of April 30, 2025. STOCKHOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED BY THE COMPANY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE ANNUAL MEETING.
Stockholders may obtain free copies of the proxy statement and other documents the Company files with the SEC from the SEC’s website at www.sec.gov or through the Investors Relations page of the Company’s website at ir.tevogen.com/financials/sec-filings/default.aspx or by contacting the Company’s Investor Relations team by e-mail at ir@tevogen.com.
Participants in the Solicitation
The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the Annual Meeting. Information regarding the Company’s directors and executive officers will be contained in the proxy statement the Company will file with the SEC. You may also find additional information about the Company’s executive officers in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on April 2, 2025 and information about the Company’s directors and about directors’ and executive officers’ ownership of Company securities in the Company’s prospectus dated August 5, 2024 that forms a part of the Company’s Registration Statement on Form S-1 (File No. 333-280414). Other information regarding the participants in the proxy solicitation will be contained in the proxy statement. To the extent that holdings of Company securities by its directors and executive officers have changed since the amounts disclosed in the prospectus, such changes have been or will be reflected in Statements of Changes in Ownership on Form 4 filed with the SEC and in the proxy statement. You can obtain or when available will be able to obtain free copies of these documents at the SEC’s website at www.sec.gov or through the Investors Relations page of the Company’s website at ir.tevogen.com/financials/sec-filings/default.aspx.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When is Tevogen Bio's (TVGNW) 2025 Annual Meeting and how can shareholders participate?
What are the key voting items at Tevogen Bio's 2025 Annual Meeting?
How can investors access Tevogen Bio's proxy materials for the 2025 Annual Meeting?
Where will Tevogen Bio publish the results of the 2025 Annual Meeting?
